Chronic wounds affect approximately 18 million individuals globally each year, presenting a significant public health challenge. These persistent wounds, often stemming from diabetic ulcers, pressure ulcers, venous ulcers, arterial ulcers, and traumatic injuries, require advanced and often long-term care. The chronic wound care market, valued at $11.6 billion in 2021, is projected to grow at a CAGR of 6.7% and reach $19.5 billion by 2029.
The stock we are bringing to your attention today is that of Cuprina Holdings (Cayman) Limited (CUPR), a Singapore-based biomedical and biotechnology company developing and commercializing innovative products for the management of chronic wounds.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com